Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of A0001 in Subjects With Friedreich's Ataxia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Individuals with genetically confirmed Friedreich's Ataxia (GAA or point mutation)~* Impaired Glucose Tolerance, measured by Oral GTT~Exclusion Criteria:~* Overt Diabetes Mellitus~* Presence of clinically significant cardiovascular disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Low Dose (Type: EXPERIMENTAL): A0001 (0.5 g BID)
- High Dose (Type: EXPERIMENTAL): A0001 (0.75 g BID)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).